Martin Reck
#103,018
Most Influential Person Now
Researcher
Martin Reck's AcademicInfluence.com Rankings
Martin Reckcomputer-science Degrees
Computer Science
#3704
World Rank
#3893
Historical Rank
Machine Learning
#515
World Rank
#521
Historical Rank
Artificial Intelligence
#723
World Rank
#734
Historical Rank
Database
#1003
World Rank
#1056
Historical Rank
Download Badge
Computer Science
Martin Reck's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Martin Reck Influential?
(Suggest an Edit or Addition)Martin Reck's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. (2015) (6804)
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. (2016) (6764)
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (2018) (3740)
- Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) (2238)
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) (2193)
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1839)
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) (1690)
- First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer (2018) (1653)
- Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. (2009) (1501)
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) (1372)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008) (1275)
- First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer (2017) (1217)
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial (2014) (959)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (2019) (907)
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. (2014) (764)
- Management of non-small-cell lung cancer: recent developments (2013) (688)
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (671)
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). (2017) (640)
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (628)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (626)
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010) (614)
- Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. (2012) (599)
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. (2012) (569)
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. (2013) (563)
- PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. (2013) (560)
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) (560)
- Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. (2010) (497)
- Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. (2017) (492)
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020) (470)
- Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (2018) (445)
- Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. (2010) (436)
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. (2021) (434)
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. (2015) (402)
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. (2016) (372)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers (2019) (364)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (355)
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula (2018) (311)
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (309)
- Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. (2006) (309)
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (2017) (306)
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. (2013) (286)
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. (2008) (266)
- Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. (2011) (262)
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. (2017) (258)
- Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. (2014) (239)
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. (2020) (232)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (231)
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021) (219)
- Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. (2008) (219)
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. (2017) (219)
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus (2020) (207)
- Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. (2012) (207)
- Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. (2009) (196)
- Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 (2007) (176)
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) (2021) (171)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. (2014) (162)
- Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. (2011) (162)
- Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (2009) (155)
- ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study (2016) (150)
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (2022) (150)
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. (2011) (149)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. (2019) (146)
- Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. (2014) (145)
- Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. (2006) (144)
- Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (138)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (133)
- Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. (2005) (131)
- NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC (2016) (130)
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study (2015) (130)
- SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. (2004) (128)
- Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer (2008) (124)
- Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. (2011) (124)
- Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study (2010) (123)
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. (2019) (123)
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. (2015) (120)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer (2020) (119)
- Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. (2020) (114)
- A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. (2015) (112)
- IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. (2021) (111)
- Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. (2021) (109)
- Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer (2016) (105)
- Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. (2021) (105)
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. (2017) (102)
- Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study (2008) (101)
- Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma (2016) (100)
- Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 (2018) (100)
- Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) (2010) (99)
- The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial (2010) (97)
- EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. (2017) (97)
- Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. (2018) (93)
- Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. (2020) (92)
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (91)
- Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study (2021) (91)
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. (2019) (90)
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. (2017) (89)
- Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? (2015) (88)
- Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026 (2017) (87)
- Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. (2003) (86)
- Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors (2019) (86)
- A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (2008) (86)
- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. (2018) (85)
- A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer (2019) (85)
- Impact of Nivolumab versus Docetaxel on Health‐Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study (2018) (84)
- Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. (2009) (84)
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. (2020) (83)
- Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations (2016) (83)
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 (2021) (83)
- The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. (2017) (81)
- Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts (2011) (81)
- Clinicopathologic Features of Advanced Squamous NSCLC. (2016) (80)
- OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% (2017) (80)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. (2021) (79)
- [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. (2011) (79)
- Challenges in lung cancer therapy during the COVID-19 pandemic (2020) (78)
- LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% (2020) (78)
- Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. (2020) (78)
- Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) (77)
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. (2018) (76)
- Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. (2019) (76)
- Targeting KRAS in non-small cell lung cancer: recent progress and new approaches. (2021) (75)
- Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion. (2016) (72)
- First-Line Immunotherapy for Non-Small-Cell Lung Cancer. (2022) (71)
- OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC (2019) (70)
- Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 (2018) (69)
- Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. (2013) (68)
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? (2015) (67)
- Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. (2014) (67)
- Targeted therapies for non-small cell lung cancer. (2010) (66)
- Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis. (2010) (66)
- How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer. (2019) (66)
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer (2021) (64)
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer (2021) (63)
- Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). (2020) (63)
- Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. (2018) (63)
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. (2021) (62)
- Anesthetic Influence on Occurrence and Treatment of the Trigemino-Cardiac Reflex (2015) (62)
- Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390) (2012) (62)
- KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. (2019) (60)
- Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. (2018) (60)
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). (2011) (59)
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. (2019) (58)
- Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer (2016) (56)
- The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. (2016) (55)
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. (2015) (55)
- Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer (2015) (55)
- Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). (2016) (54)
- Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). (2010) (54)
- [Prevention, diagnosis, therapy, and follow-up of lung cancer]. (2010) (53)
- Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer (2012) (53)
- First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update (2021) (53)
- Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. (2017) (53)
- Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer (2008) (52)
- Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. (2020) (52)
- Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression (2017) (52)
- A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. (2010) (51)
- Implications for Clinical Practice (2012) (51)
- A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer (2007) (50)
- Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment (2016) (50)
- Immunotherapy for small-cell lung cancer: emerging evidence. (2016) (50)
- What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? (2012) (49)
- IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) (2019) (49)
- Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. (2012) (49)
- A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (2014) (48)
- Determination of PD-L 1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1 / PD-L 1 Inhibitors (2019) (48)
- A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015) (2014) (47)
- Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations (2019) (46)
- KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC (2019) (46)
- Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer (2015) (44)
- LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis (2019) (43)
- Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis (2018) (43)
- PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (2011) (43)
- Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial (2007) (42)
- Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. (2004) (42)
- First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology (2014) (42)
- 96ODETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY (2015) (41)
- Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. (2010) (41)
- A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer (2010) (41)
- Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. (2010) (41)
- Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. (2017) (40)
- A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. (2013) (40)
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (40)
- LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) (2017) (39)
- An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. (2012) (39)
- Tissue sampling in lung cancer: a review in light of the MERIT experience. (2011) (38)
- Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. (2016) (38)
- Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (2020) (38)
- Nivolumab plus ipilimumab in non-small-cell lung cancer. (2019) (38)
- Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. (2013) (37)
- A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. (2013) (37)
- Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. (2009) (35)
- Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer (2010) (35)
- Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. (2016) (35)
- Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. (2006) (35)
- Targeting of MEK in lung cancer therapeutics. (2015) (35)
- Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. (2011) (34)
- Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer (2006) (34)
- OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer (2019) (34)
- ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 (2020) (34)
- Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State (2019) (33)
- First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. (2019) (33)
- Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer (2019) (33)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis (2019) (33)
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (32)
- 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy (2015) (32)
- An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer (2013) (32)
- Small cell lung cancer: a slightly less orphan disease after immunotherapy. (2021) (32)
- Immunologic checkpoint blockade in lung cancer. (2015) (32)
- Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis. (2011) (31)
- LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial (2020) (31)
- Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. (2015) (31)
- Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (2018) (31)
- IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. (2019) (30)
- Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. (2015) (29)
- Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 (2019) (28)
- CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC). (2016) (28)
- Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study (2017) (28)
- RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). (2019) (28)
- Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). (2016) (28)
- Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups (2020) (27)
- Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. (2021) (27)
- FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189 (2021) (27)
- Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). (2014) (27)
- EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. (2019) (27)
- A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. (2010) (27)
- [Therapy in elderly patients]. (2008) (27)
- P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. (2016) (27)
- Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. (2012) (27)
- Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. (2012) (26)
- Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). (2022) (26)
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial (2022) (26)
- Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer (2020) (26)
- CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC). (2016) (25)
- B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study (2007) (25)
- Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA (2020) (25)
- Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. (2011) (25)
- Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial. (2006) (24)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. (2014) (24)
- Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC (2014) (24)
- KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50% (2016) (24)
- Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. (2018) (24)
- Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. (2013) (24)
- Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS (2018) (24)
- Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer (2018) (24)
- A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC) (2007) (23)
- 134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) (2018) (23)
- Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer. (2014) (23)
- Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (23)
- DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. (2014) (23)
- Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). (2009) (22)
- Three‐Year Follow‐Up of a Randomized Phase II Trial on Refinement of Early‐Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study) (2016) (22)
- First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. (2021) (22)
- The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC (2020) (22)
- [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]. (1998) (21)
- The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC) (2008) (21)
- An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer (2017) (21)
- Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). (2019) (21)
- Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer. (2021) (21)
- Characterizing death acceptance among patients with cancer (2019) (21)
- Lung cancer in 2017: Giant steps and stumbling blocks (2018) (21)
- A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC) (2007) (20)
- Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update (2016) (20)
- Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. (2005) (20)
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (19)
- P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC (2019) (19)
- Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer (2021) (19)
- Reviewing the safety of erlotinib in non-small cell lung cancer (2011) (19)
- LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial (2020) (19)
- PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy. (2016) (19)
- Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. (2010) (19)
- Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? (2020) (19)
- MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results (2017) (18)
- The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial (2016) (18)
- Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study (2019) (18)
- Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. (2014) (18)
- Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. (2012) (18)
- Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
- Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). (2009) (18)
- Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay (2020) (18)
- Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 (2021) (18)
- Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. (2020) (17)
- Immune checkpoint blockade in small cell lung cancer. (2019) (17)
- 460PEvaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017 (2015) (17)
- 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations (2020) (17)
- Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. (2009) (17)
- Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma (2021) (17)
- Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues (2014) (17)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
- PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 (2017) (16)
- Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy (2008) (16)
- Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. (2013) (16)
- Chemotherapy in stage-IV NSCLC. (2004) (16)
- Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. (2017) (16)
- Phase II and III studies with carboplatin in small cell lung cancer. (1992) (16)
- Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. (1992) (16)
- 9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC) (2009) (16)
- PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (2011) (16)
- Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor (2015) (16)
- Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. (2018) (16)
- Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group. (2010) (16)
- Messenger RNA vaccination and B-cell responses in NSCLC patients. (2012) (16)
- Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. (2021) (16)
- An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) (2015) (15)
- Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. (2017) (15)
- Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. (2015) (15)
- 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC (2021) (15)
- 35O_PRINVESTIGATING THE UTILITY OF CIRCULATING-FREE TUMOUR-DERIVED DNA (CTDNA) IN PLASMA FOR THE DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION STATUS IN EUROPEAN AND JAPANESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC): ASSESS STUDY (2015) (15)
- A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. (2020) (15)
- Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). (2020) (15)
- Patient-reported outcomes with nivolumab in advanced solid cancers. (2018) (15)
- Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer (2015) (15)
- Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer (2017) (15)
- Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. (2018) (15)
- Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. (2021) (15)
- Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer (2018) (15)
- LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. (2017) (15)
- Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups (2018) (15)
- Prospects of targeted and immune therapies in SCLC (2018) (14)
- Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (14)
- Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC) (2008) (14)
- RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer (2021) (14)
- Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. (2012) (14)
- Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy (2019) (14)
- PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT (2019) (14)
- Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer (2013) (14)
- [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. (2014) (14)
- First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. (2021) (14)
- Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer (2019) (14)
- PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer (2014) (14)
- Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV (2020) (14)
- Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
- Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) (2016) (14)
- Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. (2012) (14)
- Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial (2021) (14)
- 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations (2020) (14)
- Perceived relatedness, death acceptance, and demoralization in patients with cancer (2019) (14)
- A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond (2010) (14)
- Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. (2020) (13)
- A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). (2014) (13)
- Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC. (2016) (13)
- A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). (2016) (13)
- MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). (2009) (13)
- Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042. (2019) (13)
- 6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer (2007) (13)
- Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). (2005) (13)
- Gefitinib in the treatment of advanced non-small-cell lung cancer (2009) (13)
- A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer (2012) (13)
- Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. (2020) (13)
- BIBF 1120 for the treatment of non-small cell lung cancer (2010) (13)
- A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. (2015) (13)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition (2010) (12)
- First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology (2021) (12)
- Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. (2019) (12)
- [ROS1-Translocations in Non-Small Cell Lung Cancer]. (2015) (12)
- Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. (2019) (12)
- 3011 Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017 (2015) (12)
- Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report (2012) (12)
- Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). (2018) (12)
- Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients (2020) (12)
- Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study (2012) (12)
- Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis (2021) (12)
- 417OPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) (2015) (12)
- Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies (2021) (12)
- Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. (2011) (12)
- 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation (2020) (12)
- Advanced non-small cell lung cancer: the role of PD-L1 inhibitors. (2018) (12)
- Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY (2020) (12)
- Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study (2018) (11)
- 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6) (2022) (11)
- UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). (2021) (11)
- Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results from an exploratory analysis of the AVAiL study. (2016) (11)
- Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects (2022) (11)
- The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma (2021) (11)
- LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen (2022) (11)
- Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib (2011) (11)
- Targeted therapy in nonsmall cell lung cancer (2009) (11)
- Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study. (2003) (11)
- Nintedanib for the treatment of patients with advanced non-small-cell lung cancer (2014) (11)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (2019) (11)
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer (2017) (11)
- Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer (2018) (11)
- Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. (2005) (11)
- Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer (2020) (11)
- Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC (2018) (10)
- A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy (2022) (10)
- Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib (2015) (10)
- Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. (2006) (10)
- 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). (2013) (10)
- LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC (2021) (10)
- Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? (2019) (10)
- STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT (2016) (10)
- 9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390) (2009) (10)
- 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer (2020) (10)
- Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer? (2020) (10)
- 144TiPCheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) (2017) (10)
- Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. (2020) (10)
- Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 (2018) (10)
- Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel (2021) (10)
- Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer. (2013) (10)
- IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) (2019) (10)
- Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. (2005) (10)
- Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy (CT) in patients with metastatic non-small cell lung cancer (NSCLC) (1999) (10)
- B1-03: Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC) (2007) (10)
- KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation. (2021) (9)
- Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results. (2005) (9)
- IMpower150: Exploratory analysis of brain metastases development. (2020) (9)
- The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC). (2019) (9)
- Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. (2022) (9)
- Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057 (2016) (9)
- Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV (2021) (9)
- 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC (2022) (9)
- Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189. (2016) (9)
- Fountain of youth for squamous cell carcinomas? On the epigenetic age of non‐small cell lung cancer and corresponding tumor‐free lung tissues (2018) (9)
- Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. (2017) (9)
- Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double‐Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation‐Positive Metastatic Non–Small‐Cell Lung Cancer (2017) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis. (2004) (9)
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 (2022) (9)
- CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. (2012) (9)
- 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) (2015) (9)
- First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions (2020) (9)
- Novel angiogenesis inhibitors in nonsmall cell lung cancer (2015) (9)
- Targeted therapies: Thalidomide in lung cancer therapy—what have we learned? (2010) (9)
- Treating Non-Small-Cell Lung Cancer First Line with Erlotinib Monotherapy in Elderly Patients: Discussion of a Case Series (2007) (9)
- Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC (2018) (8)
- MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation (2021) (8)
- 6610 POSTER Safety of bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anti-coagulation (FDAC) treated on protocol BO17704 (2007) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. (2020) (8)
- 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) (2007) (8)
- Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy (2016) (8)
- Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression (2017) (8)
- Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057. (2016) (8)
- KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC. (2021) (8)
- Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (2020) (8)
- Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany. (2018) (8)
- Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. (2022) (8)
- 9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC) (2011) (8)
- Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial. (2016) (8)
- CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC). (2012) (8)
- Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer (2019) (8)
- The tissue is the issue: improved methylome analysis from paraffin-embedded tissues by application of the HOPE technique (2014) (8)
- Immunotherapy for Lung Cancer (2016) (8)
- PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay. (2020) (7)
- RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. (2021) (7)
- LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA (2020) (7)
- Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second‐Line Treatment of Advanced Non–Small‐Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial (2017) (7)
- Pemetrexed–cisplatin combination in mesothelioma (2005) (7)
- PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword? (2017) (7)
- KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype? (2021) (7)
- PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC (2018) (7)
- Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227. (2018) (7)
- OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA (2021) (7)
- Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) (2021) (7)
- IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (2018) (7)
- Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). (2015) (7)
- OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC (2017) (7)
- 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs) (2015) (7)
- Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. (2006) (7)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration. (2019) (7)
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
- [Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]. (2017) (6)
- Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice (2021) (6)
- PS01.53: First‐Line Atezolizumab Plus Chemotherapy in Chemotherapy‐Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology (2016) (6)
- Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). (2015) (6)
- A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies (2003) (6)
- A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer (2014) (6)
- Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC) (2007) (6)
- Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). (2011) (6)
- Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. (2020) (6)
- EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients (2005) (6)
- A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744) (2012) (6)
- 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results (2021) (6)
- High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers (2019) (6)
- PD-066 Does reporting expected duration and severity of adverseevents provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel (2005) (6)
- P-202 Phase II trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer (NSCLC) (2003) (6)
- Carboplatin/etoposide/vincristine therapy in small cell lung cancer. (1992) (6)
- 43IN QUALITY OF LIFE AS AN ENDPOINT OF CLINICAL TRIALS (2009) (6)
- Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure? (2019) (6)
- MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study (2017) (6)
- Dimensionality, Stability, and Validity of the Beck Hopelessness Scale in Cancer Patients Receiving Curative and Palliative Treatment. (2016) (6)
- Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study (2016) (6)
- Atezolizumab Treatment of Nonsquamous NSCLC. (2018) (6)
- C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) (2007) (6)
- 98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA (2021) (5)
- Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006. (2019) (5)
- 9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC (2009) (5)
- KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (5)
- 1300PBUPARLISIB (BKM120) IN PATIENTS WITH PI3K PATHWAY-ACTIVATED, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM THE BASALT-1 STUDY. (2014) (5)
- Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (2018) (5)
- 1234PA RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER. (2014) (5)
- Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D). (2014) (5)
- Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives (2020) (5)
- International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. (2021) (5)
- Examining the safety profile of angiogenesis inhibitors: implications for clinical practice (2010) (5)
- AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). (2021) (5)
- Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC). (2014) (5)
- A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133) (2016) (5)
- 1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 (2020) (5)
- Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer. (2006) (5)
- Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience: 580_PR (2016) (5)
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (5)
- Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer (2017) (5)
- The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. (2022) (5)
- Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma (2021) (5)
- Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC) (2012) (5)
- Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient (2016) (5)
- PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive‐Stage SCLC: Topic: Medical Oncology (2016) (5)
- Single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: Preliminary results of a phase II randomized trial (2005) (5)
- MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC (2018) (5)
- Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial (2017) (5)
- History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature (2021) (4)
- Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
- Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…. (2018) (4)
- A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC (2011) (4)
- Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer (2021) (4)
- 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer (2017) (4)
- Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2023) (4)
- 471PEFFECT OF NINTEDANIB (BIBF 1120) COMBINED WITH STANDARD 2ND-LINE DOCETAXEL IN NSCLC PATIENTS WHO RECEIVED PRIOR PEMETREXED IN LUME-LUNG 1: A RANDOMISED, PLACEBO-CONTROLLED PHASE III TRIAL. (2014) (4)
- OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC (2018) (4)
- [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]. (2004) (4)
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2023) (4)
- P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC (2016) (4)
- Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) (2008) (4)
- PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057. (2016) (4)
- Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. (2011) (4)
- Abstract 4660: A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancer. (2013) (4)
- RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: outcomes by EGFR mutation type (2020) (4)
- eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (2017) (4)
- Diagnostics and staging procedures in non‐small cell lung cancer – is less more? (2008) (4)
- An open-label, multi centre, phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC) (2005) (4)
- Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 bySTK11andKEAP1status (2020) (4)
- Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data. (2017) (4)
- Advanced Non-Small-Cell Lung Cancer. (2017) (4)
- MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy. (2012) (4)
- CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC) (2019) (4)
- DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer (2021) (4)
- Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer. (2018) (3)
- [Therapy of Metastatic Non-small Cell Lung Cancer]. (2016) (3)
- PD-155 Molecular markers such as EGFR and kRAS mutations aspredictors of sensitivity to erlotinib in patients (pts) with NSCLC: Exploratory subanalyses of TALENT, a phase III trial (2005) (3)
- Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial. (2013) (3)
- Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) (2020) (3)
- RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). (2020) (3)
- O-109 Improved quality of life with the addition of SRL172 (killed mycobacterium vaccae) to standard chemotherapy in patients with advanced non-small cell lung cancer: Phase III results (2003) (3)
- 1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS. (2014) (3)
- Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations (2016) (3)
- Tumour biomarker and plasma time course data from ABIGAIL, a phase II study of 1st-line bevacizumab + chemotherapy in advanced non-squamous non-small-cell lung cancer (ns-NSCLC) (2012) (3)
- 6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704 (2007) (3)
- 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) (2022) (3)
- Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2016) (3)
- First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022) (3)
- Abstract 2376: Improved progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC . (2013) (3)
- A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC (2019) (3)
- O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC (2019) (3)
- Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. (2016) (3)
- Small cell lung cancer and other thoracic malignancies (2012) (3)
- 1377TiPJAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC) (2017) (3)
- Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. (2022) (3)
- RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability (2021) (3)
- IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (2018) (3)
- Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials (2022) (3)
- Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study (2019) (3)
- MA 03.06 Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC (2017) (3)
- Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC). (2015) (3)
- PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive‐Stage SCLC After First‐Line Chemotherapy: Topic: Medical Oncology (2016) (3)
- Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians (2022) (3)
- Double Homeobox Protein DUX 4 in the Human Lung: Expression under Normal and Pathological Conditions (2014) (3)
- Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC (2022) (3)
- Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC) (2016) (3)
- 473PPRIOR TAXANE USE IN THE LUME-LUNG 1 PHASE III TRIAL AND THE EFFECT ON OUTCOME FOLLOWING 2ND-LINE TREATMENT WITH NINTEDANIB (BIBF 1120) AND DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC. (2014) (3)
- eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. (2018) (3)
- 9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx) (2011) (3)
- Pharmacogenomics in NSCLC: mostly unsexy but desperately needed. (2014) (3)
- Targeting the immune system for management of NSCLC: the revival? (2013) (3)
- Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset (2021) (3)
- 111 Chemotherapy of limited stage small cell lung cancer with carboplatin, paclitaxel and oral etoposide-A phase II-trial (1997) (3)
- Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. (2022) (3)
- Pembrolizumab in Non-Small-Cell Lung Cancer. (2017) (3)
- OA02.03 Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 (2021) (3)
- Clinical Genotyping and Efficacy Outcomes: Exploratory Biomarker Data from the Phase II Abigail Study of 1st-Line Bevacizumab + Chemotherapy in Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC) (2012) (2)
- An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC) (2016) (2)
- MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). (2009) (2)
- P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (2)
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
- 188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) (2018) (2)
- Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer. (2016) (2)
- 1364PFinal clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer (2016) (2)
- 119PA phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts (2017) (2)
- Incidence of brain metastases in patients treated with bevacizumab (2013) (2)
- DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) (2012) (2)
- Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC. (2015) (2)
- 1298P RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship (2020) (2)
- 6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study (2007) (2)
- [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer]. (2016) (2)
- eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. (2018) (2)
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023) (2)
- PLS. plenary session (2012) (2)
- 438PEfficacy of nintedanib/docetaxel in East Asian patients with lung adenocarcinoma (ADE): analysis from the LUME-Lung 1 study (2015) (2)
- P1.13-02 eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients (2018) (2)
- Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study. (2015) (2)
- Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance (2019) (2)
- A Multi-Center Phase II Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody Amatuximab in Combination with Chemotherapy for Frontline Therapy of Malignant Pleural Mesothelioma: Updated Clinical Outcomes and Correlative Studies (2012) (2)
- 153P Real-world study of NSCLC with EGFR exon 20 insertions (2021) (2)
- PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results (2021) (2)
- [Response judgement - conventional versus new methods]. (2009) (2)
- 194TiP eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients (2018) (2)
- A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC) (2008) (2)
- Efficacy of afatinib in the clinical practice: Final results of the GIDEON study in EGFR mutated non-small cell lung cancer (NSCLC) in Germany. (2020) (2)
- [Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT]. (2011) (2)
- [Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]. (2006) (2)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer (2014) (2)
- [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. (2005) (2)
- MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib (2008) (2)
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer (2023) (2)
- 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status (2021) (2)
- Patients with brain metastases treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON (2019) (2)
- Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. (2019) (2)
- Maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the Phase III SQUIRE study. (2015) (2)
- Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas (2021) (2)
- 9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer (2009) (2)
- Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133). (2017) (2)
- Rash as a marker for the efficacy of necitumumab in the SQUIRE Study (2015) (2)
- Advanced non-small cell lung cancer therapy: historical and future perspectives (2008) (2)
- [Non-small cell lung cancer - diagnostics and stage-adapted therapy]. (2007) (2)
- 356TiPPhase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC (2015) (2)
- KEYNOTE‐024 Update: Pembrolizumab vs Platinum‐Based Chemotherapy for Advanced NSCLC with PD‐L1 Tumor Proportion Score ≥50%: PS3 (2018) (2)
- 6512 ORAL Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT study (2007) (2)
- 122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 (2021) (2)
- 78MO Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6) (2021) (2)
- Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study. (2014) (2)
- P1.15-05 Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial) (2022) (2)
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
- VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo) (2021) (2)
- Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON. (2019) (2)
- 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA (2022) (1)
- 158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry (2022) (1)
- P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (2017) (1)
- Erlotinib: evaluation as a first-line treatment option for elderly patients with advanced non-small-cell lung cancer (NSCLC) (2008) (1)
- New Approaches in Immunotherapy (2015) (1)
- Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis. (2022) (1)
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as fi rst-line treatment in patients with advanced non-small-cell lung cancer (2012) (1)
- Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799. (2021) (1)
- Surgery and radiotherapy versus radiotherapy in patients with small-cell lung cancer (SCLC) responding to chemotherapy with paclitaxel, etoposide phosphate, and carboplatin (TEC) - analysis of a randomized phase- II-trial: P1-209 (2007) (1)
- KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer. (2021) (1)
- PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 (2019) (1)
- 6607 POSTER Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC) (2007) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non–Small-Cell Lung Cancer (NSCLC) (2022) (1)
- EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC (2022) (1)
- [Analysis of treatment outcomes in two patient cohorts (2004-2005 and 2007-2008) with limited and extensive disease small-cell lung cancer]. (2011) (1)
- PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598 (2021) (1)
- 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT) (2021) (1)
- Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival. (2019) (1)
- P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT (2016) (1)
- Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide. (2022) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC (2022) (1)
- 3066 Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study (2015) (1)
- 1377P Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC (2020) (1)
- P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study (2018) (1)
- 6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study (2007) (1)
- Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012. (2021) (1)
- Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression (2022) (1)
- Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry (2022) (1)
- 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours (2019) (1)
- 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up (2022) (1)
- Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non‐small‐cell lung cancer in Spain: ASSESS study: 147P (2016) (1)
- A randomised multi-centre phase-II trial to assess the effect of dose splitting of carboplatin (CARBO) in comparison to a single application of carboplatin in a gemcitabine (GEM)/carboplatin regime for stage IIIB and IV non small cell lung cancer (NSCLC) (2005) (1)
- 1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome (2021) (1)
- [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]. (2008) (1)
- Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis: 59PD (2016) (1)
- MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150 (2021) (1)
- PL 03.04 Current Status and Future of Immunotherapy in Lung Cancer (2017) (1)
- 1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI (2022) (1)
- CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx) (2019) (1)
- Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) (2019) (1)
- Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany (2019) (1)
- Initial safety results of an expanded access program (EAP) of erlotinib in non-small cell lung cancer (NSCLC). (2006) (1)
- Targeted Therapy und Precision Medicine (2016) (1)
- 進行性NSCLC患者におけるカルボプラチンとパクリタキセルを併用した,TRAIL-R1アゴニスト単クローン抗体マパツムマブの無作為化第2相試験 (2010) (1)
- P2.04-012 First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study (2017) (1)
- 3077 65 plus: A randomized phase III trial of Pemetrexed and Bevacizumab vs. Pemetrexed, Bevacizumab and Carboplatin as 1st line treatment for elderly patients with advanced non-squamous, non-small cell lung cancer (NSCLC) - a subgroup analysis of age and gender (2015) (1)
- Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’ (2021) (1)
- P3-134: Sunitinib in combination with gemcitabine plus cisplatin for advanced non–small cell lung cancer (NSCLC): preliminary results from a phase I dose escalation study (2007) (1)
- Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). (2017) (1)
- RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts). (2020) (1)
- Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC) (2020) (1)
- Plasma biomarkers in a phase II trial of sorafenib in advanced non-small cell lung cancer (2007) (1)
- P1.01-108 PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC (2019) (1)
- 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC (2011) (1)
- NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy. (2022) (1)
- Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply. (2021) (1)
- 1267PQUALITY-OF-LIFE (QOL), TOLERABILITY, AND SUPPORTIVE CARE RESULTS: NECITUMUMAB PHASE 3 SQUIRE STUDY. (2014) (1)
- P75.04 Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC (2021) (1)
- FP14.12 Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3. (2021) (1)
- Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival. (2022) (1)
- 44 – Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer (2018) (1)
- Review of Pulmonary Hemorrhage (PH) in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Bevacizumab and Cisplatin plus Gemcitabine on Protocol BO17704 (2007) (1)
- OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 (2021) (1)
- Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials? (2020) (1)
- 40 POSTER Update on survival in a phase Ib/ll study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2006) (1)
- MET alterations in NSCLC-Current Perspectives and Future Challenges. (2022) (1)
- Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC). (2022) (1)
- P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057: Track: Immunotherapy. (2016) (1)
- P-558 Phase-II trial of topotecan and etoposide in extensive disease small cell lung cancer (ED-SCLC) (2003) (1)
- Immunotherapy: the third wave in lung cancer treatment. (2015) (1)
- Lung Cancer in Germany. (2022) (1)
- Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer. (2010) (1)
- Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreatedEGFRmutation-positive metastatic NSCLC: Next generation sequencing (NGS) results (2020) (1)
- 1382TiPInvestigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study (2017) (1)
- OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer (2021) (1)
- [New developments in treatment of non-small cell lung cancer]. (2013) (1)
- 1115 POSTER Epidermal Ggrowth Factor Receptor Inhibitor (EGFRI)-associated rash: a suggested novel management paradigm. A consensus position from the EGFRI Dermatologic Toxicity Forum (2007) (1)
- Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results. (2017) (1)
- Canopy-2: Phase 3 Study of Canakinumab plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC (2019) (1)
- MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (1)
- 9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study (2009) (1)
- 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC (2011) (1)
- [Lung cancer : What has been confirmed in therapy?] (2017) (1)
- RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship (2022) (1)
- The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours (2016) (1)
- OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results (2017) (1)
- Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC). (2011) (1)
- Effects of chemotherapy on ipilimumab-mediated increases in absolute lymphocyte count and activation of T cells (2012) (1)
- Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients (2022) (1)
- Plasma ctDNA for the detection of EGFR mutation status in advanced nsclc (aNSCLC) as per local diagnostic practices: Japanese subset data from assess. (2016) (1)
- 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results (2022) (1)
- Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? (2014) (1)
- EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC (2022) (1)
- Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography (2022) (0)
- 1230P Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany (2021) (0)
- 963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315 (2022) (0)
- Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer (2016) (0)
- 58TiPIMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC (2017) (0)
- Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containig regimen (2008) (0)
- [Treatment of small-cell lung cancer]. (2011) (0)
- [Therapeutic standards and perspectives for stage IV non-small cell lung cancer]. (2012) (0)
- 9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC (2009) (0)
- 3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC (2015) (0)
- [Non-small cell lung cancer: news from immunotherapy]. (2015) (0)
- Carboplatin in small cell lung cancer. (1991) (0)
- Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression (2017) (0)
- 1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315) (2022) (0)
- ESMO Asia 2016 Congress Highlights Monday (2016) (0)
- Discussion: Evaluation of Current Clinical Status and Future Directions in Small Cell Lung Cancer (1992) (0)
- KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. (2022) (0)
- Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. (2023) (0)
- Health‐Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non‐Squamous NSCLC: KEYNOTE‐189: PD.1.01 (2018) (0)
- EP16.01-011 PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC (2022) (0)
- 1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (2017) (0)
- Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma. (2023) (0)
- Lungenkarzinom Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer (2017) (0)
- Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study (2016) (0)
- Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]. (2021) (0)
- A blood-based miRNA signature predicts immunotherapy efficacy in advanced stage non-small cell lung cancer (2021) (0)
- Contents, Supplement 1, 1992 (1992) (0)
- CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden: PS2 (2018) (0)
- Systemic treatment of non-small cell lung cancer in the metastatic stage. Quo vadis (2014) (0)
- 1309P A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) (2021) (0)
- EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315 (2022) (0)
- [Follow-up, complications and their treatment in the surgical, radiotherapeutic and pharmacological treatment of lung cancer]. (2011) (0)
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer (2023) (0)
- P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol (2019) (0)
- The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. (2023) (0)
- P-488 Phase II randomized trial of single-agent pemetrexed orsequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy (2005) (0)
- Analysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials (2019) (0)
- Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- P-563 Splitted dose carboplatin (CARBO) in comparison with singledose carboplatin in a gemcitabine(GEM)/Carboplatin schedule for stage IIIb and IV non-small cell lung cancer (NSCLC) — a randomised multi-centre phase II trial (2005) (0)
- Final efficacy and safety results of ECOG Performance Status (PS) subgroup analyses from the SQUIRE phase III study (2015) (0)
- P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era (2021) (0)
- Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC) (2020) (0)
- Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient. (2015) (0)
- ROS1-Translokationen im nicht-kleinzelligen Lungenkarzinom ROS1-Translocations in Non-Small Cell Lung Cancer (2015) (0)
- Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598. (2021) (0)
- Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1. (2023) (0)
- [A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients]. (2014) (0)
- 1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery (2020) (0)
- Response to Letter to the Editor. (2017) (0)
- Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122) (2023) (0)
- Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy (2019) (0)
- Supplementary Material for: Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) (2016) (0)
- 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status (2021) (0)
- Combinations Therapies. (2015) (0)
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer (2022) (0)
- Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315) (2019) (0)
- Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2017) (0)
- [CT-Screening for Lung Cancer - what is the Evidence?] (2018) (0)
- presented as P 2 . 46 ) LCSS as a Marker of Treatment Bene fi t With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 (2016) (0)
- PS04.02 Randomized, Double-Blind Study of Erlotinib Plus Ramucirumab or Placebo in First Line for Patients with EGFR Mutation-Positive Metastatic NSCLC: Topic: Medical Oncology (2017) (0)
- 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression (2022) (0)
- Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. (2022) (0)
- Placenta-derived conditioned medium with anti-tumor properties on human NSCLC (2015) (0)
- OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100 (2022) (0)
- Phase II trial of mitomycin (MMC) and gemcitabine (GEM) in patients with advanced non small cell lung cancer (2000) (0)
- First — line chemotherapy in SCLC: a phase III study of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristin (CEV) (2001) (0)
- [Anti-angiogenic strategy: therapy optimization of non-squamous non-small cell lung carcinoma]. (2014) (0)
- Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs) (2017) (0)
- A randomized, double-blind, placebo-controlled phase II study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer (NSCLC). (2012) (0)
- OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update (2023) (0)
- Lungenkarzinoms Anti-angiogenic Strategy : Therapy Optimization of Non-squamous Non-small Cell Lung Carcinoma (2014) (0)
- 140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC (2021) (0)
- Latest innovations in NSCLC management (2012) (0)
- nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) (2021) (0)
- Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315 (2022) (0)
- SY4-1 Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies (2021) (0)
- Abstract CT066: HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor (2023) (0)
- Immunotherapy Is Evolving and Promising for Lung Cancer (2015) (0)
- P1.01-58 Comprehensive Serial Biomaterial Acquisition in Advanced NSCLC: Feasibility, Challenges and Perspectives (2019) (0)
- Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC): A Network Meta-Analysis vs. New Therapeutic Options (2016) (0)
- 557TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (2021) (0)
- Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients (2023) (0)
- RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset (2019) (0)
- SC26.03 Predictive Biomarkers for Angiogenesis Inhibitors: An Update (2017) (0)
- Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. (2019) (0)
- IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen (2022) (0)
- [Current developments and perspectives in targeted therapies]. (2010) (0)
- EP08.01-057 Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS (2022) (0)
- Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+ (2018) (0)
- 139TiPA non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS) (2017) (0)
- Lungenkarzinom Therapy of Metastatic Non-small Cell Lung Cancer (2016) (0)
- P1.13-30 Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial (2018) (0)
- 37IN HOW TREATMENT IS DONE NOW BASED ON EGFR/KRAS MUTATIONS AND ALK; STANDARD TREATMENT IN 2011 (2011) (0)
- 30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial (2014) (0)
- 3102 Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: Analysis of data from the LUME-Lung 1 study (2015) (0)
- Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. (2022) (0)
- Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. (2020) (0)
- First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors (2012) (0)
- First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. (2023) (0)
- V-122 Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315 (2021) (0)
- PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227 (2023) (0)
- Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update (2022) (0)
- Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients (2023) (0)
- Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). (2021) (0)
- Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT (2014) (0)
- 483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC (2016) (0)
- Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression (2017) (0)
- 120PSubgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC) (2017) (0)
- 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023) (0)
- 521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC) (2016) (0)
- 3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results (2015) (0)
- P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+ (2018) (0)
- Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer (2020) (0)
- 6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by (2007) (0)
- 969TiP Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006 (2022) (0)
- 146TiPEXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (2017) (0)
- P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease (2021) (0)
- RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. (2023) (0)
- Nintedanib Plus Docetaxel Improves PFS and OS for Patients with Stage IIIB/IV or Recurrent Lung Adenocarcinoma (2013) (0)
- Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 ( (2022) (0)
- Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC). (2017) (0)
- P61.03 Comparison of the Sensitivity of Different Screening Algorithms to Select Lung Cancer Patients for Screening in a Cohort of German Patients (2021) (0)
- The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies. (2013) (0)
- P-207 Docetaxel and irinotecan as first line chemotherapy in patients with unresectable locally advanced or metastatic non small cell lung cancer (NSCLC): A phase II study (2003) (0)
- P-495 Indisulam (E7070) in combination with carboplatin in patientswith locally advanced/metastatic non-small cell lung cancer (NSCLC) — A phase II study (2005) (0)
- Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (0)
- [Non-small-cell carcinoma of the lung with invasive Aspergillus infection after chemotherapy]. (2011) (0)
- 1371P Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): results from an EORTC pan-European survey. (2017) (0)
- Real-world data for precision cancer medicine - a European perspective. (2023) (0)
- MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker (2021) (0)
- 152P Immunotherapy for extensive-stage SCLC: Uncovering clinical gaps in physician knowledge and practice (2022) (0)
- Garon et al 2014 Lancet Supplument (2014) (0)
- [Immunotherapy for non-small cell lung cancer (NSCLC)]. (2022) (0)
- Second-line therapy of non-small cell lung cancer (2012) (0)
- 1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (2022) (0)
- PO-0779 Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey (2019) (0)
- Maintenance Pemetrexed (PEM) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC after PEM Plus Cisplatin for Advanced Nonsquamous NSCLC (2012) (0)
- Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC) (2019) (0)
- MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey (2019) (0)
- PD-154 An open-label, multi centre phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC) (2005) (0)
- P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors (2021) (0)
- Advanced Non-Small-Cell Lung Cancer. (2017) (0)
- P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC (2019) (0)
- [Treatment of non-small cell lung cancer]. (2011) (0)
- P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
- OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA (2021) (0)
- 1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC) (2020) (0)
- Personalized medicine in non-small- cell lung cancer: has it come of age? (2011) (0)
- 523 Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade (2022) (0)
- Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. (2023) (0)
- ASSESS: EGFR Mutations Can Be Analyzed With ctDNA (2015) (0)
- Outcomes of patients = 70 years of age in PACIFIC (2019) (0)
- 118P The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small cell lung cancer (2021) (0)
- OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology (2017) (0)
- [Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide]. (1990) (0)
- The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice? (2022) (0)
- SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). (2021) (0)
- SPACE-Studie (2019) (0)
- DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer (2021) (0)
- 3032 A non-comparative, single-arm observational study conducted as a non-interventional study (NIS) to monitor the routine clinical practice of bevacizumab in combination with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in G (2015) (0)
- P3.01-071 Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes (2017) (0)
- [TTF-1-negative lung adenocarcinoma: special features of systemic treatment]. (2023) (0)
- EP08.02-060 How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry (2022) (0)
- Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. (2018) (0)
- EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC) (2022) (0)
- TGF-ß on the loose: How downregulation of BAMBI contributes to perturbed signaling in NSCLC (2016) (0)
- PARAMOUNT : phase 3 comparant un traitement (ttt) de maintenance par Pemetrexed (Pem) plus soins de support (BSC) versus placebo plus BSC après un ttt d’induction par Pem-Cisplatine (Cispt) dans les CBNPC non épidermoïdes avancés (2011) (0)
- KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (0)
- P47.01 SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress) (2021) (0)
- P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants (2021) (0)
- Randomized, open-label phase Ib/II study of atezolizumab with or without daratumumab in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). (2017) (0)
- PACIFIC-6: A phase II study of durvalumab after sequential chemoradiotherapy in patients with unresectable Stage III NSCLC (2020) (0)
- 155TiP Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC) (2022) (0)
- 188PMOLECULAR PROFILING OF NON-SMALL CELL LUNG CANCER WITH CYTOLOGIC SPECIMENS IN THE ABSENCE OF HISTOLOGIC SPECIMENS. (2014) (0)
- Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
- 65INIMMUNOTHERAPY: CURRENT STATUS. (2014) (0)
- 1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC) (2022) (0)
- 1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC) (2022) (0)
- Bevacizumab in routine clinical practice for first-line therapy with platinum-based chemotherapy of patients with advanced adenocarcinoma of the lung in Germany (2016) (0)
- 1266PQUALITY OF LIFE (QOL) RESULTS FROM THE PHASE 3 REVEL STUDY OF RAMUCIRUMAB + DOCETAXEL (RAM + DTX) VERSUS PLACEBO + DOCETAXEL (PL + DTX) IN ADVANCED/METASTATIC NSCLC PATIENTS (PTS) WITH PROGRESSION AFTER PLATINUM BASED CHEMOTHERAPY. (2014) (0)
- Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). (2018) (0)
- B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC) (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Martin Reck?
Martin Reck is affiliated with the following schools:
